Meta-analysis: The impact of diabetes mellitus on the immunological response to hepatitis B virus vaccine in dialysis patients

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 7, 2011, Pages 815-821

  Fabrizi, F ^a   Dixit, V ^b   Martin, P ^b   Messa, P ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ADULT; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIALYSIS; DRUG RESPONSE; FEMALE; GENETIC HETEROGENEITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; SEROLOGY;

DIABETES MELLITUS; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; RENAL DIALYSIS; STATISTICS AS TOPIC; TIME FACTORS;

EID: 79952254830     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04589.x     Document Type: Review

References (38)

1. Labriola L, Jadoul M,. The decades-long fight against HBV transmission to dialysis patients: slow but definite progress. Nephrol Dial Transplant 2010; 25: 2047-9.
2. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ,. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18: 52-61. (Pubitemid 40348277)
3. Thompson ND, Perz JF, Moorman AC, Holmberg SD,. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008. Ann Intern Med 2009; 150: 33-9.
4. Burdick RA, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2003; 63: 2222-9. (Pubitemid 36605835)
5. Rangel M, Coronado V, Euler G, Strikas R, for the Advisory Committee on Immunzation Practices and the American Academy of Pediatrics. Vaccine recommendations for patients on chronic dialysis. Semin Dial 2002; 13: 101-7.
6. Pozzilli P, Arduini P, Visalli N, et al. Reduced protection against hepatitis B virus following vaccination in patients with type 1 (insulin-dependent) diabetes. Diabetologia 1987; 30: 817-9. (Pubitemid 17163009)
7. Alavian SM, Tabatabaei S,. The effect of diabetes mellitus on immunological response to hepatitis B virus vaccine in individuals with chronic kidney disease: a meta-analysis of clinical trials. Vaccine 2010; 28: 3773-7.
8. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88. (Pubitemid 17189972)
9. Petitti DB,. Approaches to heterogeneity in meta-analysis. Statist Med 2001; 20: 3625-33. (Pubitemid 33114432)
10. Higgins JPT, Thompson SG, Deeks JI, Altman DG,. Measuring inconsistencies in meta-analysis. Br Med J 2003; 327: 557-60.
11. Galbraith RF,. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988; 7: 889-94.
12. Klein S, Simes J, Blackburn GL,. Total parenteral nutrition and cancer clinical trial. Cancer 1986; 58: 1378-86. (Pubitemid 16053158)
13. Waite N, Thomson L, Goldstein M,. Successful vaccination with intradermal hepatitis B vaccine in hemodialysis patients previously nonresponsive to intramuscular hepatitis B vaccine. J Am Soc Nephrol 1995; 5: 1930-4.
14. Fabrizi F, Di Filippo S, Marcelli D, et al. Recombinant hepatitis B vaccine use in chronic hemodialysis patients. Nephron 1996; 72: 536-43.
15. Mettang T, Schenk U, Thomas S, et al. Low dose intradermal versus intramuscular hepatitis B vaccination in patients with end-stage renal failure. Nephron 1996; 72: 192-6.
16. Jha R, Lakhtakia S, Jaleel MA, Narayan G, Hemlatha K,. Granulocyte macrophage colony stimulating factor induced seroprotection in end stage renal failure patients to hepatitis B in vaccine non responders. Ren Failure 2001; 23: 629-36. (Pubitemid 33055235)
17. Eardley K, Jones H, Osman H, Smith S,. Efficacy of the accelerated hepatitis B vaccination schedule used in haemodialysis patients post-exposure to virus: a single-centre experience. Nephrol Dial Transplant 2002; 17: 1982-7. (Pubitemid 35277098)
18. Chin A,. Hepatitis B virus vaccine response in hemodialysis: baseline patient characteristics. Hemodial Int 2003; 7: 296-303.
19. Elwell R, Neumann M, Bailie G,. Factors associated with long-term antibody production induced by hepatitis B vaccine in patients undergoing haemodialysis: a retrospective cohort study. Pharmacotherapy 2003; 23: 1558-63. (Pubitemid 37485308)
20. Liu YL, Kao M, Huang C,. A comparison of responsiveness to hepatitis B vaccination in patients on hemodialysis and peritoneal dialysis. Vaccine 2005; 23: 3957-60. (Pubitemid 40726189)
21. Chow K, Law M, Leung C, Szeto C, Li P,. Antibody response to hepatitis B vaccine in end-stage renal disease patients. Nephron Clin Pract 2006; 103: c89-93. (Pubitemid 43952607)
22. Ocak S, Eskiocack A,. The evaluation of immune responses to hepatitis B vaccination in diabetic and non-diabetic haemodialysis patients and the use of tetanus toxoid. Nephrology 2008; 13: 487-91.
23. Afsar B, Elsurer R, Eyileten T, Yilmaz M, Caglar K,. Antibody response following hepatitis B vaccination in dialysis patients: Does depression and life quality matter? Vaccine 2009; 27: 5865-9.
24. Chow KM, Lo S, Szeto C, et al. Extra-high dose hepatitis B vaccination does not confer longer serological protection in peritoneal dialysis patients: a randomized controlled trial. Nephrol Dial Transplant 2010; 25: 2303-9.
25. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G,. Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease. Aliment Pharmacol Ther 2004; 20: 1053-62. (Pubitemid 39657938)
26. Fernandez E, Betru MA, Gomez R, Montoliu J,. Response to the hepatitis B virus vaccine in haemodialysis patients: influence of malnutrition and its importance as a risk factor for morbidity and mortality. Nephrol Dial Transplant 1996; 11: 1559-63. (Pubitemid 26252723)
27. Ahuja TS, Kumar S, Mansoury H, Rodriguez H, Kuo YF,. Hepatitis B vaccination in human immunodeficiency virus-infected adults receiving haemodialysis. Kidney Int 2005; 67: 1136-41. (Pubitemid 41623340)
28. Navarro JF, Teruel JL, Mateos ML, Marcen R, Ortuno J,. Antibody level after hepatitis B vaccination in haemodialysis patients: influence of hepatitis C virus infection. Am J Nephrol 1996; 16: 95-7. (Pubitemid 26050662)
29. Pol S, Legendre C, Mattlinger B, Berthelot P, Krein H,. Genetic basis of nonresponse to hepatitis B vaccine in hemodialysis patients. J Hepatol 1990; 11: 385-7.
30. Jibani MM, Heptonstall J, Walker AM, Bloodworth LO, Howard AJ,. Hepatitis B immunization in UK renal units: failure to put policy into practice. Nephrol Dial Transplant 1994; 9: 1765-8.
31. Alper CA, Kruskall MS, Marcus-Bagley D, et al. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 1989; 321: 708-12. (Pubitemid 19239702)
32. Lacson E, Teng M, Ong J, Vienneau L, Ofsthun N, Lazarus J,. Antibody response to Engerix-B and Recombivax-HB hepatitis B vaccination in end stage renal disease. Hemodial Int 2005; 9: 367-75. (Pubitemid 41614648)
33. DaRoza G, Loewen A, Durdjev O, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis 2003; 42: 1184-92. (Pubitemid 37486762)
34. Morais E, Resende M, Oliveira A, et al. Intradermal hepatitis B vaccination in patients with advanced chronic renal failure: immunogenicity and follow-up. Aliment Pharmacol Ther 2007; 25: 849-55. (Pubitemid 46434916)
35. Edey M, Barraclough K, Johnson DW,. Review article: hepatitis B and dialysis. Nephrology 2010; 15: 137-45.
36. Ono K, Kashiwagi S,. Complete seroconversion by low dose intradermal injection of recombinant hepatitis B vaccine in hemodialysis patients. Nephron 1991; 58: 47-51.
37. Marangi AL, Giordano R, Montanaro A, et al. Hepatitis B virus infection in chronic uraemia: long-term follow-up of a two-step integrated protocol of vaccination. Am J Kidney Dis 1994; 23: 537-42. (Pubitemid 24109115)
38. Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic haemodialysis patients. MMWR 2001; 50: 1-43.